Igeneon Licenses Cancer Vaccine from Novartis
By Business Review Editor
Pharma Deals Review: Vol 2002 Issue 29 (Table of Contents)
Published: 2 Oct-2002
DOI: 10.3833/pdr.v2002.i29.992 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Igeneon entered into a licensing agreement with Novartis for an anti-idiotypic antibody cancer vaccine, IGN301 that targets epithelial antigens for the treatment of epithelial cancers...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS